TACSTD2 and posterior cortical atrophy: Consistent with their demonstrated role in immunoediting (for the first time, to the best of our knowledge), we also provided some preclinical evidence that the GSE1/TACSTD2 ratio reflects abiraterone/enzalutamide and castration resistance in patients with PCa and that targeting GSE1 signaling suppresses metastatic and cancer stemness phenotypes and enhances sensitivity to abiraterone or enzalutamide in metastatic castration-resistant PCa in vitro and in vivo (Figure 6 and Figure 7).